ABSTRACT
BACKGROUND: Recently, peak atrial longitudinal strain (PALS) has emerged as a possible predictor of Cancer therapy-related cardiac dysfunction (CTRCD) in cancer patients (CP), in addition to left ventricular global longitudinal strain (GLS). Thus, considering the link between left atrium and left ventricle, the aim of this study was to assess the global atrio-ventricular strain (GAVS) in CP, to detect early cardiotoxicity. METHODS: A prospective study was carried out enrolling 131 breast cancer women (mean age 51.4 ± 10.4 years) receiving anti-cancer treatment. Clinical and echocardiographic evaluation was performed at baseline (T0), 3 (T1), 6 (T2) and 12 months (T3) after starting treatment. CTRCD was defined according to the 2022 ESC Cardio-Oncology guidelines. RESULTS: Forty-four patients developed CTRCD (3 moderate and 41 mild CTRCD group A) and 87 patients did not (group B). In group A, significant changes in GLS, PALS, GAVS, LASi (left atrial stiffness index) and LVEF/GLS occurred earlier than LVEF, that reduced significantly only at T3 (p-value < .05). Significant changes in LASi, PALS and GAVS occurred even in group B but reduction in GAVS (-21% vs. -5%) and PALS (-24% vs. -12%) was significantly greater in group A compared to group B (p-value = .04). CONCLUSIONS: Our study confirms high sensitivity of speckle tracking echocardiography in detecting subclinical myocardial damage in CP and the usefulness of a multiparametric echocardiographic evaluation including PALS and GLS (GAVS) for having a global evaluation of the phenomenon cardiotoxicity.
Subject(s)
Breast Neoplasms , Echocardiography , Humans , Female , Breast Neoplasms/complications , Middle Aged , Echocardiography/methods , Prospective Studies , Cardiotoxicity/physiopathology , Cardiotoxicity/etiology , Heart Ventricles/diagnostic imaging , Heart Ventricles/physiopathology , Heart Atria/diagnostic imaging , Heart Atria/physiopathology , Antineoplastic Agents/adverse effects , Reproducibility of ResultsABSTRACT
BACKGROUND: Anthracyclines can cause left ventricular (LV) dysfunction. There is little data about right ventricular (RV) damage during chemotherapy. AIM: This study aimed to investigate the toxic effects of chemotherapy, analyzing its impact on right ventricular function. MATERIAL AND METHODS: A prospective study was conducted, enrolling 83 female patients (55 ± 11 years old) affected by breast cancer treated with anthracyclines. Cardiological evaluation, HFA risk score assessment and comprehensive echocardiogram, including speckle tracking analysis and 3D analysis, were performed before starting chemotherapy (T0) and at 3 (T1), 6 (T2) and 12 months (T3) after beginning treatment. RV function was assessed with tricuspid annular plane excursion (TAPSE), S' wave of the tricuspid annulus, fractional area change (FAC), RV global longitudinal strain (RV-GLS), free wall strain (RV-FWLS) and RV 3D ejection fraction (RV-3DEF). Subclinical LV CTRCD was defined as a reduction of GLS > 15% compared to baseline. Subclinical RV cardiotoxicity was defined as the co-presence of a relative decrease of 10% from baseline in RV-3DEF and a relative reduction of 15% from baseline RV-FWLS. RESULTS: After chemotherapy, we found a significant reduction in 2D-LVEF (p = < 0.001) and 3D-LVEF (p = < 0.001), in LV-GLS and RVLS (p = < 0.001), in FAC and TAPSE, also RV-3DEF reduced significantly (p = 0.002). 39% of patients developed LV subclinical CTRCD; 28% of patients developed RV subclinical cardiotoxicity. LV and RV changes occurred concomitantly, and no RV echocardiographic parameters were found to predict the development of LV CTRCD and vice-versa. CONCLUSION: After anthracyclines-based chemotherapy, LV and RV subclinical damage occurs, and it can be detected early by speckle-tracking and 3D echocardiography.
ABSTRACT
BACKGROUND: The 2022 ESC Guidelines on Cardio-Oncology recommend baseline cardiovascular risk stratification before starting anticancer drugs, using the new risk assessment tools proposed by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS).Our study aimed to assess the clinical application of HFA/ICOS risk score in breast cancer patients undergoing chemotherapy and its usefulness in predicting the development of chemotherapy-related cardiac dysfunction (CTRCD). METHODS: A prospective multicentric study enrolled 109 breast cancer patients treated with anthracyclines with or without trastuzumab. A cardiological evaluation, including ECG and echocardiogram at baseline (T0), 3 (T1), 6 (T2), and 12âmonths (T3) after starting treatment was performed. HFA/ICOS score was assessed in all patients. The population was divided into low, medium, high, and very-high risk.During follow-up, CTRCD and other cardiovascular events have been evaluated. RESULTS: 61 patients were low risk, 37 medium, 9 high, 2 very-high risk criteria. We found a significantly higher incidence of overall cardiotoxicity (CTRCD and other cardiovascular events) in the very-high risk group (100%) compared with the medium (29%) and low risk groups (13%). CTRCD incidence was also significantly higher in the high risk group (55%). CTRCD resulted as being associated with baseline arterial hypertension and baseline HFA/ICOS risk score of high ( p â=â0.006) or very-high ( p â<â0.0001). CONCLUSION: Our study confirms the HFA/ICOS score's ability to predict cardiovascular toxicity in breast cancer women and the need for close monitoring especially in high and very-high risk patients.
Subject(s)
Antineoplastic Agents , Breast Neoplasms , Heart Diseases , Heart Failure , Humans , Female , Breast Neoplasms/drug therapy , Prospective Studies , Antineoplastic Agents/adverse effects , Heart Failure/chemically induced , Heart Failure/diagnosis , Heart Failure/drug therapy , Cardiotoxicity , Inducible T-Cell Co-Stimulator ProteinABSTRACT
AIMS: Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin. METHODS AND RESULTS: A retrospective single-centre observational study was carried out on 58 patients (32 men and 26 women; mean age ± SD: 59 ± 15 years) with CML treated with TKIs for a median period of 43 ± 31 months. Cardiological evaluation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment tool proposed by HFA/ICOS. AEs were recorded. According to SCORE charts and the new HFA/ICOS risk stratification tool, respectively, 46% (Group A1) and 60% (Group A2) of patients were at high-very high risk, and 54% (Group B1) and 40% (Group B2) at low-moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (P value < 0.01) when considered overall; they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA/ICOS risk stratification tool was significantly more sensitive than SCORE (P < 0.01) in identifying patients at higher risk of cardiovascular toxicity. In addition, we did not find AEs in patients pretreated with aspirin. CONCLUSIONS: The new HFA/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patients with CML and it is more sensitive than SCORE charts.
Subject(s)
Heart Failure , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Adult , Aged , Aspirin , Cardiotoxicity/etiology , Chronic Disease , Female , Heart Failure/complications , Heart Failure/epidemiology , Humans , Inducible T-Cell Co-Stimulator Protein , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Retrospective Studies , Risk AssessmentABSTRACT
OBJECTIVEBoth spontaneous and iatrogenic spondylodiscitis are becoming ever more frequent, yet there are no definite treatment guidelines. For many years the treatment protocol was conservative medical management or surgical debridement with patients immobilized or bedridden for weeks and often resulting in spinal deformity. The eventual development of spinal deformity can be difficult to treat. Over the last few years, the authors have preferred a single-approach instrumented arthrodesis when spondylolysis that evolves in deformity from somatic wedging occurs.METHODSThe authors retrospectively reviewed the clinical, radiological, and surgical records of 11 patients treated over the past 3 years for spondylodiscitis with osteosynthesis.RESULTSOverall, the authors treated 11 patients: 3 cases with tuberculous spondylodiscitis (1 dorsal, 2 lumbar); 6 cases with Staphylococcus aureus spondylodiscitis (1 cervical, 2 dorsal, 2 lumbar, 1 dorsolumbar); 1 spondylodiscitis with postsurgical lumbar deformity; and in 1 dorsolumbar case the germ was not identified. Surgical approaches were chosen according to spinal level: In 8 dorsolumbar cases a posterior osteosynthesis was achieved. In 1 cervical case an anterior approach was performed with autologous bone graft from iliac crest. In 2 thoracolumbar cases a posterolateral costotransversectomy was needed. In 1 lumbosacral case iliac somatic grafting was used. Ten patients received adequate antibiotic treatment with clinical remission, and 1 case is in initial follow-up. No complications due to instrumentation were recorded. Spinal deformity was prevented in 10 cases, whereas preexisting spinal deformity was partially corrected in 1 case. In all cases, arthrodesis achieved vertebral stability.CONCLUSIONSThis study has the limitations of a retrospective review with a limited number of patients. Instrumentation does not appear to hamper healing from infection. Moreover, spinal stabilization, which is assisted by the infectious process even in the absence of bone graft, allows early mobilization. Instrumented osteosynthesis should be preferred for spondylodiscitis with osteolysis and spinal instability because it allows early mobilization and rehabilitation whenever necessary. It prevents spinal deformity and does not hamper healing of infections.